Altimmune (ALT) Shares Outstanding (Diluted Average) (2014 - 2026)

Altimmune (ALT) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $124.5 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $124.5 million, up 64.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $124.5 million (up 64.75% YoY), and the FY2025 annual result was $88.1 million, up 24.08% from the prior year.
• Shares Outstanding (Diluted Average) improved to $124.5 million in Q1 2026 per ALT's latest filing, from $88.1 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $124.5 million in Q1 2026 and troughed at $44.0 million in Q1 2022.
• A 5-year average of $66.0 million and a median of $70.8 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Diluted Average) advanced 6.12% in 2023, then surged 64.75% in 2026.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $46.9 million in 2022, then increased by 13.47% to $53.2 million in 2023, then surged by 33.35% to $71.0 million in 2024, then rose by 24.08% to $88.1 million in 2025, then jumped by 41.27% to $124.5 million in 2026.
• Business Quant data shows ALT's Shares Outstanding (Diluted Average) at $124.5 million in Q1 2026, $88.1 million in Q4 2025, and $82.2 million in Q3 2025.